View in EDS HTML Full Text PDF Full Text

Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations.

Saved in:
Bibliographic Details
Title: Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations.
Authors: DeLeon TT; Department of Hematology & Oncology, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America., Almquist DR; Department of Hematology & Oncology, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America., Kipp BR; Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America., Langlais BT; Department of Biostatistics, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America., Mangold A; Department of Dermatology, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America., Winters JL; Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America., Kosiorek HE; Department of Biostatistics, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America., Joseph RW; Department of Hematology & Oncology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America., Dronca RS; Department of Hematology & Oncology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America., Block MS; Department of Hematology & Oncology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America., McWilliams RR; Department of Hematology & Oncology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America., Kottschade LA; Department of Hematology & Oncology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America., Rumilla KM; Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America., Voss JS; Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America., Seetharam M; Department of Hematology & Oncology, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America., Sekulic A; Department of Dermatology, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America.; Mayo Clinic Cancer Center, Phoenix, Arizona, United States of America., Markovic SN; Department of Hematology & Oncology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America., Bryce AH; Department of Hematology & Oncology, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America.
Source: PloS one [PLoS One] 2020 Mar 20; Vol. 15 (3), pp. e0230306. Date of Electronic Publication: 2020 Mar 20 (Print Publication: 2020).
Publication Type: Journal Article
Journal Info: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 32196516
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22DeLeon+TT%22">DeLeon TT</searchLink>; Department of Hematology & Oncology, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America.<br /><searchLink fieldCode="AU" term="%22Almquist+DR%22">Almquist DR</searchLink>; Department of Hematology & Oncology, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America.<br /><searchLink fieldCode="AU" term="%22Kipp+BR%22">Kipp BR</searchLink>; Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America.<br /><searchLink fieldCode="AU" term="%22Langlais+BT%22">Langlais BT</searchLink>; Department of Biostatistics, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America.<br /><searchLink fieldCode="AU" term="%22Mangold+A%22">Mangold A</searchLink>; Department of Dermatology, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America.<br /><searchLink fieldCode="AU" term="%22Winters+JL%22">Winters JL</searchLink>; Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America.<br /><searchLink fieldCode="AU" term="%22Kosiorek+HE%22">Kosiorek HE</searchLink>; Department of Biostatistics, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America.<br /><searchLink fieldCode="AU" term="%22Joseph+RW%22">Joseph RW</searchLink>; Department of Hematology & Oncology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America.<br /><searchLink fieldCode="AU" term="%22Dronca+RS%22">Dronca RS</searchLink>; Department of Hematology & Oncology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America.<br /><searchLink fieldCode="AU" term="%22Block+MS%22">Block MS</searchLink>; Department of Hematology & Oncology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America.<br /><searchLink fieldCode="AU" term="%22McWilliams+RR%22">McWilliams RR</searchLink>; Department of Hematology & Oncology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America.<br /><searchLink fieldCode="AU" term="%22Kottschade+LA%22">Kottschade LA</searchLink>; Department of Hematology & Oncology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America.<br /><searchLink fieldCode="AU" term="%22Rumilla+KM%22">Rumilla KM</searchLink>; Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America.<br /><searchLink fieldCode="AU" term="%22Voss+JS%22">Voss JS</searchLink>; Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America.<br /><searchLink fieldCode="AU" term="%22Seetharam+M%22">Seetharam M</searchLink>; Department of Hematology & Oncology, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America.<br /><searchLink fieldCode="AU" term="%22Sekulic+A%22">Sekulic A</searchLink>; Department of Dermatology, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America.; Mayo Clinic Cancer Center, Phoenix, Arizona, United States of America.<br /><searchLink fieldCode="AU" term="%22Markovic+SN%22">Markovic SN</searchLink>; Department of Hematology & Oncology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America.<br /><searchLink fieldCode="AU" term="%22Bryce+AH%22">Bryce AH</searchLink>; Department of Hematology & Oncology, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101285081%22">PloS one</searchLink> [PLoS One] 2020 Mar 20; Vol. 15 (3), pp. e0230306. <i>Date of Electronic Publication: </i>2020 Mar 20 (<i>Print Publication: </i>2020).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Public+Library+of+Science%22">Public Library of Science </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101285081 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1932-6203 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2219326203%22">19326203 </searchLink><i>NLM ISO Abbreviation: </i>PLoS One <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=32196516
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1371/journal.pone.0230306
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e0230306
    Titles:
      – TitleFull: Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: DeLeon TT
      – PersonEntity:
          Name:
            NameFull: Almquist DR
      – PersonEntity:
          Name:
            NameFull: Kipp BR
      – PersonEntity:
          Name:
            NameFull: Langlais BT
      – PersonEntity:
          Name:
            NameFull: Mangold A
      – PersonEntity:
          Name:
            NameFull: Winters JL
      – PersonEntity:
          Name:
            NameFull: Kosiorek HE
      – PersonEntity:
          Name:
            NameFull: Joseph RW
      – PersonEntity:
          Name:
            NameFull: Dronca RS
      – PersonEntity:
          Name:
            NameFull: Block MS
      – PersonEntity:
          Name:
            NameFull: McWilliams RR
      – PersonEntity:
          Name:
            NameFull: Kottschade LA
      – PersonEntity:
          Name:
            NameFull: Rumilla KM
      – PersonEntity:
          Name:
            NameFull: Voss JS
      – PersonEntity:
          Name:
            NameFull: Seetharam M
      – PersonEntity:
          Name:
            NameFull: Sekulic A
      – PersonEntity:
          Name:
            NameFull: Markovic SN
      – PersonEntity:
          Name:
            NameFull: Bryce AH
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 20
              M: 03
              Text: 2020 Mar 20
              Type: published
              Y: 2020
          Identifiers:
            – Type: issn-electronic
              Value: 1932-6203
          Numbering:
            – Type: volume
              Value: 15
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: PloS one
              Type: main
ResultId 1